Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION StudyAdrian Minson, Emma Verner, Pratyush Giri, et al.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Cancer Journal|July 8, 2024
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remissionMazyar Shadman, Kwang W Ahn, Manmeet Kaur, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Blood|December 17, 2015
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donorsAbraham S Kanate, Alberto Mussetti, Mohamed A Kharfan-Dabaja, et al.
Blood|December 9, 2022
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapyAnnatina S Schnegg-Kaufmann, Julie A I Thoms, Golam Sarower Bhuyan, et al.
British Journal of Haematology|March 19, 2016
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantationTimothy S Fenske, Kwang W Ahn, Tara M Graff, et al.
Leukemia & Lymphoma|March 8, 2017
Report of the 6th International Workshop on PET in lymphomaCristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, et al.
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Pageof 9